Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Analyst consensus is “Hold”: Of nine analysts, five rate Bicycle Therapeutics a buy, three recommend holding, and one recommends selling. The average 12-month price target is $13.86 versus the stock’s recent price of $4.10.
• Shares remain near their 52-week low: BCYC opened at $4.10, compared with a 52-week range of $3.74 to $9.16. The company reported a quarterly EPS loss of $0.72, missing expectations, while revenue of $0.63 million was well below the $4.22 million consensus estimate.
• Institutional ownership is high, while insiders have recently sold: Institutional investors and hedge funds own 86.15% of the company, and several large holders increased their positions. Insiders sold 9,977 shares worth approximately $42,702 over the past 90 days, including a CEO sale made to cover tax obligations.

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been assigned an average recommendation of "Hold" from the nine analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $13.8571.

A number of research analysts recently weighed in on BCYC shares. Wall Street Zen upgraded Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, August 15th. Needham & Company LLC dropped their price target on Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. Citigroup restated a "market outperform" rating on shares of Bicycle Therapeutics in a report on Wednesday, June 3rd. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th.

Insider Buying and Selling

In related news, CEO Kevin Lee sold 5,905 shares of the firm's stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the transaction, the chief executive officer owned 605,408 shares in the company, valued at approximately $2,585,092.16. This trade represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 9,977 shares of company stock valued at $42,702 in the last 90 days. Company insiders own 22.00% of the company's stock.

Institutional Investors Weigh In On Bicycle Therapeutics

Large investors have recently made changes to their positions in the business. Fcpm Iii Services B.V. raised its stake in shares of Bicycle Therapeutics by 0.5% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,468,430 shares of the company's stock valued at $24,556,000 after acquiring an additional 16,100 shares during the period. Armistice Capital LLC boosted its position in Bicycle Therapeutics by 8.7% during the 4th quarter. Armistice Capital LLC now owns 3,236,000 shares of the company's stock worth $22,911,000 after purchasing an additional 258,000 shares during the period. Westfield Capital Management Co. LP boosted its position in Bicycle Therapeutics by 2.2% during the 4th quarter. Westfield Capital Management Co. LP now owns 3,016,026 shares of the company's stock worth $21,353,000 after purchasing an additional 63,483 shares during the period. GSK plc acquired a new stake in Bicycle Therapeutics in the 4th quarter valued at $10,829,000. Finally, Principal Financial Group Inc. increased its holdings in Bicycle Therapeutics by 2.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,174,625 shares of the company's stock valued at $5,450,000 after purchasing an additional 26,353 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company's stock.

Bicycle Therapeutics Stock Down 0.7%

NASDAQ:BCYC opened at $4.10 on Wednesday. The company has a market cap of $286.97 million, a P/E ratio of -1.50 and a beta of 1.55. The firm's 50 day moving average is $4.14 and its two-hundred day moving average is $4.57. Bicycle Therapeutics has a fifty-two week low of $3.74 and a fifty-two week high of $9.16.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.14). The company had revenue of $0.63 million for the quarter, compared to analysts' expectations of $4.22 million. Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. Research analysts forecast that Bicycle Therapeutics will post -2.26 earnings per share for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company's core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source